Dupilumab (Dupixent®) is accepted for restricted use within NHSScotland

Use is restricted in adults and adolescents with severe asthma who have blood eosinophils ≥150 cells/microlitre and FeNO ≥25 parts per billion, and ≥4 exacerbations in the preceding year, and have previously received biologic treatment with anti-IgE or anti-IL-5 therapies.

Source:

Scottish Medicines Consortium